Mitochondria-targeted MXene nanozyme MS@PMXene-TK promotes mitophagy and inhibits `cGAS/STING` inflammation, protecting cartilage in OA mice.
Background
Osteoarthritis (OA) is a debilitating joint disease marked by progressive cartilage degradation, mitochondrial dysfunction, and chronic inflammation, for which disease-modifying treatments remain elusive. Current therapeutic strategies often fail due to poor targeting and rapid clearance, leaving a critical gap in addressing the intertwined pathologies of oxidative stress and inflammation at the cellular level. Specifically, mitochondrial reactive oxygen species (ROS) and subsequent mitochondrial DNA (mtDNA) leakage are key drivers of the inflammatory cGAS/STING pathway in chondrocytes, exacerbating cartilage damage. Developing targeted interventions that can precisely modulate chondrocyte mitochondrial health and inflammatory responses is crucial for effective OA therapy.
Study Design
Researchers engineered MS@PMXene-TK, an innovative mitochondria-targeted nanozyme, integrating a chondro-inductive peptide (SPPEPS)-loaded, polydopamine-modified MXene core with a ROS-responsive thioketal-linked polyethylene glycol shell and a mitochondria-targeting peptide (MTP-131). This design aimed for precise subcellular delivery. In vitro analyses evaluated its ability to scavenge mitochondrial ROS and restore mitochondrial function within chondrocytes. For in vivo assessment, MS@PMXene-TK was administered via intra-articular injection into an anterior cruciate ligament transection (ACLT)-induced OA mouse model. Primary endpoints included evaluation of cartilage protection, subchondral bone integrity, chondrogenic marker expression, extracellular matrix synthesis, and modulation of macrophage-mediated inflammatory responses.
Results
In vitro and in vivo studies confirmed that MS@PMXene-TK effectively scavenged mitochondrial ROS within chondrocytes, acting as a "cruise missile" to restore mitochondrial membrane potential. This led to a significant promotion of mitophagy, a crucial process for clearing damaged mitochondria. > This cascade effectively mitigated mtDNA leakage and subsequent activation of the cGAS/STING pathway, a critical inflammatory driver in OA. Concurrently, the sustained release of SPPEPS enhanced chondrogenic marker expression and extracellular matrix synthesis, while alleviating macrophage-mediated inflammatory responses, further modulating the inflammatory microenvironment. In the ACLT-induced OA mouse model, intra-articular administration of MS@PMXene-TK significantly improved cartilage protection and subchondral bone integrity, demonstrating its multi-modal therapeutic efficacy.
Why It Matters
This research introduces a highly promising multi-modal strategy for OA treatment by simultaneously addressing mitochondrial dysfunction, oxidative stress, and inflammation. The mitochondria-targeted nanozyme MS@PMXene-TK offers a novel approach to disease modification in OA, moving beyond symptomatic relief. By precisely targeting chondrocyte mitochondria and inhibiting the cGAS/STING inflammatory pathway, this platform could disrupt the core pathologies driving OA progression. The integration of a chondro-inductive peptide further supports cartilage repair, suggesting a comprehensive therapeutic benefit. While currently preclinical, this work lays the groundwork for developing targeted, disease-modifying therapies that could fundamentally alter the course of OA, potentially leading to more effective and durable patient outcomes.